[Media Feature] Tumour Markers and Genetic Testing – Can They Truly Enable Early Detection?

As medical technologies advance rapidly, public interest in early detection tools such as tumour marker tests and commercially available genetic testing kits has grown. However, experts advise that these tools are not one-size-fits-all solutions, and their results should be interpreted with caution.

DxD Hub was featured in a recent Channel 8 “Hello Singapore” segment that explored the benefits and limitations of such diagnostic tools. Dr. Weng Ruifen, CEO of DxD Hub, shared insights on the clinical use of genetic testing and the importance of scientific rigour in ensuring accurate, meaningful results. She emphasized that while medical-grade genetic testing has become an important part of clinical care, particularly in identifying cancer-related gene mutations to guide treatment decisions, many consumer-facing products lack the same level of validation.

We collaborate closely with ecosystem partners including Singapore General Hospital and Lucence to co-develop innovative diagnostic solutions. One such initiative is the development of urine-based testing methods for early detection of urological cancers, offering a non-invasive and more accessible alternative to current methods.

At DxD Hub, we remain committed to translating deep tech into practical healthcare applications. By supporting robust research, clinical validation, and public education, we aim to empower patients and healthcare providers with accurate, evidence-based tools for early detection and better health outcomes.